ABSTRACT
Introduction Hospitalisations relating to acute respiratory deteriorations (ARD) in Interstitial Lung Disease (ILD) have poor outcomes. Factors predicting adverse outcomes are not fully understood and data addressing the use of illness severity scores in prognostication are limited.
Objective To validate the use of CURB-65 and NEWS-2 severity scores to predict mortality following ARD-ILD hospitalisation.
Methods A dual-centre prospective observational cohort study of all adults (≥18y) hospitalised with ARD-ILD in Bristol, UK (n=179). Gender-Age-Physiology (GAP), CURB-65 and NEWS-2 scores were calculated for each eligible admission.
Receiver operating characteristics (ROC) curve analysis was used to quantify the strength of discrimination for NEWS-2 and CURB-65 scores. Univariable and multivariable logistic regression analyses were performed to explore the relationship between baseline severity scores and mortality.
Results GAP showed some merit at predicting 30-day mortality (AUC=0.64, P=0.015); whereas CURB-65 showed modest predictive value for in-hospital (AUC=0.72, P<0.001) and 90-day mortality (AUC=0.67, P<0.001). NEWS-2 showed higher predictive value for in-hospital (AUC=0.80, P<0.001) and 90-day mortality (AUC=0.75, P<0.001), with an optimal derived cut-off ≥6.5 found to be sensitive and specific for predicting in-hospital (83% and 63%) and 90-day (73% and 72%) mortality. In exploratory analyses, GAP score addition improved the predictive ability of NEWS-2 against 30-day mortality and CURB-65 across all time-periods.
Conclusion NEWS-2 has good discriminatory value for predicting in-hospital mortality and moderate discriminatory value for predicting 90-day mortality. The optimal NEWS-2 cut-off value determined was the same as in a previous retrospective cohort, confirming the NEWS-2 score shows promise in predicting mortality following ARD-ILD hospitalisation.
What is the key question?
- Can NEWS-2 and CURB-65 be used to predict inpatient mortality in a cohort of patients with acute respiratory deterioration on a background of known interstitial lung disease?
What is the bottom line?
- The NEWS-2 score shows high sensitivity and specificity in predicting both 90-day and in-hospital mortality in patients hospitalised with ARD-ILD
- Whilst the CURB-65 score showed high sensitivity for predicting mortality, there was a low specificity, and did not add value to the predictive ability of the NEWS-2 score.
Why read on?
- This analysis included 179 patients from two study sites and provides, for the first time, prospective evidence for utilising NEWS-2 and CURB-65 as tools to predict in-hospital and post hospitalisation morbidity.
Competing Interest Statement
CH is Principal Investigator of the AvonCAP study, which is an investigator-led University of Bristol study funded by Pfizer, Inc, and is currently a member of the BTS Pulmonary Infection Specialty Advisory Group (SAG). AF is a member of the Joint Committee on Vaccination and Immunization (JCVI) and chair of the World Health Organization European Technical Advisory Group of Experts (WHO ETAGE) committee. In addition to receiving funding from Pfizer as Chief Investigator for this study, he leads another project investigating transmission of respiratory bacteria in families jointly funded by Pfizer and the Gates The other authors declare no competing interests.
Clinical Protocols
https://www.isrctn.com/ISRCTN17354061
Funding Statement
The AvonCAP study is an investigator-led University of Bristol sponsored study which was designed and implemented collaboratively with Pfizer, Inc. which also funded the study. For the current manuscript, Pfizer staff did not play any part in data collection, analysis plan, data analysis or manuscript preparation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Health Research Authority East of England Ethics Committee, including use of Section 251 of the 2006 NHS Act approved by the Confidentiality Advisory Group (REC:20/EE/0157, ISRCTN:17354061)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data used in this study are sensitive and cannot be made publicly available without breaching patient confidentiality regulations. Therefore, individual participant data and a data dictionary are not available to other researchers.
